Gui-mei Lin

Dr. Gui-mei Lin

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2014 in Molecular Pharmaceutics
Verified
Journal Article
Open access
GLGui-mei Lin
Gui-mei Lin
HZHong Zhang
Hong Zhang
Leaf HuangLeaf Huang
Leaf Huang
The massive amount of human genetic information already available has accelerated the identification of target genes, making gene and nucleic acid therapy the next generation of medicine. Nanoparticle (NP)-based anticancer gene therapy treatment has received significant interest in this evolving field. Recent advances in vector technology have improved gene transfection efficiencies of nonviral vectors to a level similar to viruses. This review serves as an introduction to surface modifications of NPs based on polymeric structural improvements and target moieties. A discussion regarding the future perspective of multifunctional NPs in cancer therapy is also included.

6 November 2020 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
XFXianglei Fu
Xianglei Fu
YSYanbin Shi
Yanbin Shi
TQTongtong Qi
Tongtong Qi
SQShengnan Qiu
Shengnan Qiu
YHYi Huang
Yi Huang
GLGui-mei Lin
Gui-mei Lin
Therapeutic efficacy against cancer relies heavily on the ability of the therapeutic agents to reach their final targets. The optimal targets of most cancer therapeutic agents are usually biological macromolecules at the subcellular level, which play a key role in carcinogenesis. Therefore, to improve the therapeutic efficiency of drugs, researchers need to focus on delivering not only the therapeutic agents to the target tissues and cells but also the drugs to the relevant subcellular structures. In this review, we discuss the most recent construction strategies and release patterns of various cancer cell subcellular-targeting nanoformulations, aiming at providing guidance in the overall design of precise nanomedicine. Additionally, future challenges and potential perspectives are illustrated in the hope of enhancing anticancer efficacy and accelerating the translational progress of precise nanomedicine.

6 November 2021 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
HLHengxin Liu
Hengxin Liu
LWLi Wang
Li Wang
GLGui-mei Lin
Gui-mei Lin
YFYihua Feng
Yihua Feng
The latest progress relating to the fabrication of materials for wearable sensors, including flexible materials, electrode materials, and new biodegradable materials, is reviewed. We think flexible materials will have broad application prospects.

1 September 2018 in Journal of Controlled Release
Verified
Journal Article
Closed access
ZGZili Gu
Zili Gu
QWQingjie Wang
Qingjie Wang
YSYanbin Shi
Yanbin Shi
YHYi Huang
Yi Huang
JZJing Zhang
Jing Zhang
GLGui-mei Lin
Gui-mei Lin

1 March 2017 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
YFYang Fan
Yang Fan
CCCong Chen
Cong Chen
YHYiheng Huang
Yiheng Huang
FZFang Zhang
Fang Zhang
GLGui-mei Lin
Gui-mei Lin

1 November 2019 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
XFXianglei Fu
Xianglei Fu
YSYanbin Shi
Yanbin Shi
HWHui Wang
Hui Wang
XZXiaogang Zhao
Xiaogang Zhao
QSQifeng Sun
Qifeng Sun
GLGui-mei Lin
Gui-mei Lin
Purpose: Thymosin β-4(Tβ-4) is a macromolecular protein drug with potential for drug development in wound repair but is limited by the shortcomings of macromolecular protein, such as large volumes, poor membrane permeability, and unstable physicochemical characteristics. Ethosomes could enhance cell membrane fluidity and reduce epidermal membrane density to make macromolecular drugs through the stratum corneum into the deeper layers of the skin easily. Herein, we developed and characterized a novel transdermal delivery vehicle to load macromolecular protein peptides and use Tβ-4 as a model drug wrapped into ethosomes. Methods: We used the orthogonal method to optimize the formulation of the ethosome preparation prepared by the ethonal infusion method. Ethosomal gels were characterized by using different analytical methods. Transdermal release rate in vitro have been demonstrated in Franz diffusion cells and the efficacy of drug-loaded nanocarriers in vivo was investigated in a mouse model. Results: Optimized Tβ-4 ethosomal gels have good physicochemical properties. The drug amounts of the cumulative release in the ethosomal gel within 5 hours were 1.67 times that of the T-β4 gel in vitro release study, and the wound healing time of ethosomal gel group was only half of the T-β4 gel group in vivo pharmacokinetic study. Compared with the free drug group, the ethosome preparation not only promotes the percutaneous absorption process of the macromolecular protein drugs but also shortened wound recovery time. Conclusion: Hence, we provide a possible good design for ethosomal gel system that can load macromolecular protein peptide drugs to achieve transdermal drug administration, promoting the percutaneous absorption of the drug and improving the effect.